management of cancer patients
DESCRIPTION
With thw evolution of the medicine and increasing of the survival rate of cancer patients , its commonly to be seen in dental clinics. OMFS must know about their patients conditions , treatments and how to manage them in order to provide them good care and good life.TRANSCRIPT
![Page 1: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/1.jpg)
Management of Patients Undergoing Cancer Therapy
Hanan Shanab
![Page 2: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/2.jpg)
• Few information obtained from cancer pt. which is relevant to the surgeon. .. Like:
– The type of treatment.– The duration of treatment .– Whether he is an outpatient or inpatient
![Page 3: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/3.jpg)
(1) surgery; (2) radiation therapy.(3) Chemotherapy.
There are three treatment modalities involved in eradicating head and neck cancer:
![Page 4: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/4.jpg)
Combination Chemoradiotherapy
• Cetuximab is a chimeric monoclonal antibody that targets epidermal growth factor receptor. The FDA approved cetuximab for treatment of squamous cell carcinoma of the head and neck in March 2006.
![Page 5: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/5.jpg)
Treatment modalities involved in eradicating head and neck cancer:
(1) surgery; (2) radiation therapy.(3) Chemotherapy.
(1) Immunotherapy(2) Gene therapy.(3) Antiangiogenic therapy.
![Page 6: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/6.jpg)
Pt . Evaluation before cancer therapy:
– Age of the pt.– Condition of dentition.– Level of oral hygiene and pt. attitude.– Radiation field and dose.
![Page 7: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/7.jpg)
Guidelines for extraction before RTx
• All questionable ,carious teeth in the field of radiation (>6000 cG) must be extracted.
• Optimal time for extraction is 21 days before the beginning of RTx (not less than 2 w).
![Page 8: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/8.jpg)
• Less optimally, extraction can be done within 4 months after completion of RTx.(after HBO)
• Perform radical alveolectomy with primary soft tissue closure following extraction.
![Page 9: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/9.jpg)
Radiotherapy
• More effective on well oxygenated and mitotically active..– Induce cell necrosis .– Microvascular damage.– Parenchyma and stromal damage.
![Page 10: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/10.jpg)
Types of Radiation therapy
1-External beam radiation.– (tumoricidal dose is 6000-7600 cGy)– Hyperfractionated to 200 cGy for 5 days/week.– 150-180 cGy twice daily-3-4 days/week
2- Interstitial Radiotherapy (brachytherapy).RadiumIridium- ½ life 74 days-no gaseous by product
3-Neutron Beam Radiotherapy.Rarely used today
![Page 11: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/11.jpg)
Chemotherapy
TYPES:
• Alkylating agents • Antibiotics.
•Antimetabolites.•Hormons.•Mitotic inhibitors
CCS CCNS
![Page 12: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/12.jpg)
Complication of Cancer Therapy
![Page 13: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/13.jpg)
Complication of Cancer Therapy
• 1-Mucositis.• 2- Xerostomia.• 3-secondary infection.• 4- bleeding.• 5-Muscle Trismus.• 6-osteoradionecrosis.• 7-alopecia.
![Page 14: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/14.jpg)
– More in non keratinized tissues like palatal , buccal mucosa , ventral tongue ..
– Started by the second week of radiation therapy.(if the dose 200 cGy/week)
– 7th -14th day after chemotherapy.
Complications of Cancer Therapy
1-Mucositis.
![Page 15: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/15.jpg)
• More higher in young pt…high division rate.
• Produce red,raw, tender oral mucosa with sloughing epi. ..Like burn..
• Pt. has dysphagia, pain, loss of taste difficulty in eating which increase systemic infection.
Complication..Mucositis.
Its generally subsides 1-2 weeks after completion of treatment.
![Page 16: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/16.jpg)
WHO Scale for Oral Mucositis
• Degree 0:is when there are no signs or symptoms. • Degree 1 :is when the mucosa is erythematose and painful. • Degree 2 :is characterized by ulcers, and the patient can eat
normally.
![Page 17: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/17.jpg)
• Degree 3 :is when the patient has ulcers and can only
drink fluids. • Degree 4 :is when the patient cannot eat or drink.
![Page 18: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/18.jpg)
Phases of Mucositis
![Page 19: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/19.jpg)
Phase 1 (Initiation): radiation or chemotherapy causes DNA damage in basal epithelial cells and generates reactive oxygen species (ROS), which further damage cells and blood vessels in the submucosa.
![Page 20: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/20.jpg)
Phase 2 (Signaling): chemotherapy, radiation, induce apoptosis and upregulated inflammatory cytokines in cells.
![Page 21: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/21.jpg)
Phase 3 (Amplification): inflammatory cytokines produce further tissue damage, amplifying signaling cascades and the injury process.
![Page 22: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/22.jpg)
Phase 4 (Ulceration): loss of mucosal integrity produces extremely painful lesions, providing portals of entry for bacteria, viruses, and fungi.
![Page 23: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/23.jpg)
• Phase 5 (Healing): proliferation, differentiation, and migration of epithelial cells to restore the integrity of the mucosa.
![Page 24: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/24.jpg)
Management of Mucositis
• 1-A bland mouth rinse (salt and water).. To keep ulcerated areas clean as possible.
• 2-Topical anesthesia and /or antihistamine solution or with coating agents (milk of magnesia).
![Page 25: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/25.jpg)
• 3-Anti microbial-Chlorohixidine.12%
• 4-Anti-inflammatory or topical steroids.
• 5-Diet consisting of soft food, proteins, and vitamins supplements at therapeutic level.
Management of Mucositis
![Page 26: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/26.jpg)
• 6-Oral lubricants and lip palm ..containing (beeswax).
• 7-Avoidance of alcohol, tobacco and irritant foods
![Page 27: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/27.jpg)
2-Xerostomia
• If major salivary gland have been irradiated.
• Occur following the onset of mucositis.– Altered taste sensation.– Increase susceptibility for caries and mucosal
inflammation.– Difficult in swallowing, speech.
![Page 28: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/28.jpg)
• Side effects of pain medicine: Opioids for painful swallowing may cause dry mouth and constipation.
![Page 29: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/29.jpg)
• Recommended sugarless lemon drops.
• Sorbitol-based chewing gum.
• Buffered solution of glycerine and water or salivary substitutes.
Management of Xerstomia
![Page 30: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/30.jpg)
3-Secondary infection:
Causes:• Decrease in quantity of salivary flow.• Immunosuppressed (WBC<2000/mm3).• In pt. receiving chemotherapy and antibiotics.
![Page 31: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/31.jpg)
Fungal infection
• Candida albicans• Candidal infection produce pain, burning taste and
intolerance to certain foods.• The most common type is pseudomembranous
candidiasis.. Curdled milk
• Other forms (angular cheilosis and less common hypertrophic form.
![Page 32: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/32.jpg)
Bacterial infection
• Shift occurs in the oral flora to gram –ve that’s Normally inhabit the GIT or respiratory tract like Pseudomonas, Klebsielaa, Proteus, E coli, Enterobacter.
![Page 33: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/33.jpg)
Viral infection
• Recurrent herpes simplex (HSV).• Occur often during chemotherapy and less
frequent with radiotherapy.• Takes longer to heal.• Mimic aphthous ulcer on nonkeratinized mucosa.
![Page 34: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/34.jpg)
Management of Infection
• Cytology study.• Culture any non
healed ulcerations for Dx and for accurate treatment.
![Page 35: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/35.jpg)
For Candida infection :
– Oral nystatin suspention 100,000 IU/ml 4-5 times daily.
– Cotrimazole (10mg 5 times daily).– Systemic ketoconazol(Nizoral).– Alternatively, putting pt. on granulocyte (monocyte)
colony-stimulating factor to elevate neutrophil count to normal.
Management of Infection
![Page 36: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/36.jpg)
For Viral infection:
• Enzyme-linked immunoassay for accurate Dx.
• For HSV antibody-positive pt:– Acyclovir, famcyclovir, valcyclovir.– Daily dose of at least 1 g.
Management of Infection
![Page 37: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/37.jpg)
4- Bleeding
• Pt. undergo total body irradiation• High dose chemotherapy.
Thrombocytopenia
![Page 38: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/38.jpg)
• Clinical signs:– Plat. <50,000 cells/mm3– Petechia, purpra on lateral margin of tongue.– Gingival bleeding.– Submucosal hemorrhage… from minor trauma
![Page 39: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/39.jpg)
Management of Bleeding
• Avoid trauma to the oral cavity.• Control bleeding by local measures by
– Pressure.– Gelatine sponge.– Thrombin or microfibrillar collagen.– Antifibrinolytic rinse .. Amicar syrup 250mg/ml. on
soft vinyl mouth guard.• Platelet transfusion in sever cases.
![Page 40: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/40.jpg)
5-Neural and chemosensory changes
• Diminshed taste sensation… damage of microvilli of taste cells.
• Pt on chemotherapy complaints of – bitter taste, – unpleasent odors – conditioned aversion of foods
![Page 41: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/41.jpg)
• Neurotoxicity effect from chemotherapy (vincristine and vinblastin).
• Occur in peripheral nerves.• Pt. experience pain in molar area bilateral.
![Page 42: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/42.jpg)
Management
• 1-Restore taste sensation within 3-4 months after completion of radiotherapy.
• 2-In chronic loss of taste, zinc supplementation.
Silverman recommends 220 mg of zinc 2x/day.
• 3-No effective treatment for completely restores damaged taste.
![Page 43: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/43.jpg)
6-Muscle Trismus
• Caused by radiation therapy.
• Damage to the vasculature of ms.(obliterative endoartritis).
![Page 44: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/44.jpg)
– Progressive later dysphagia from fibrosis in the pharyngeal musculature
– reduces nutritional intake
– promotes aspiration.
Muscle Trismus
![Page 45: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/45.jpg)
• Pneumonia and respiratory failure: Patients who have trouble swallowing may aspirate when trying to eat or drink.
• Poor nutrition: Being unable to swallow normally makes it hard to eat well. Wounds heal more slowly and the body is less able to fight off infections.
• Use of tubefeeding: A patient who is not able to take in enough food by mouth may be fed through a tube.
![Page 46: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/46.jpg)
management
• Mouth block should be placed during radiotherapy.
• Perform daily stretching exercises to improve trismus. By using tongue plates for 3 times aday for 10 min
• Apply warm, moist heat on the area.
Muscle Trismus
![Page 47: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/47.jpg)
7-Osteoradionecrosis
• Exposed bone for 6 months after high dose of radiation.
• Results from:– Radiation.– Three-H tissue.(hypocellularity,hypoxia, hypovascularity)
– Tissue breakdown..necrosis
– nonhealing wound.
![Page 48: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/48.jpg)
• The mandible more affected than maxilla
When the radiation dose is >7500 cGy.
![Page 49: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/49.jpg)
• Clinically..– Exposed bone, loss of soft tissue and bone.– Pain (dysesthesia/anasthesia).– Pathological fracture and orocutaneous fistula.– Trismus.– Soft tissue necrosis.
![Page 50: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/50.jpg)
• Radiographic..– Diffuse radiolucency without sclerotic demarcation.– Mottled osteoporosis and sclerotic areas after bone sequestra are
formed.
![Page 51: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/51.jpg)
Management of ORN
![Page 52: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/52.jpg)
Conservative management
• Daily local irrigation..salineor chlorohixidine.2%
• Systemic antibiotics.
• Avoidance of irritants..tobaco,alcohol,denture.
• Good oral hyigene instructions.
• General removal of sequestrum in sequestrating lesions.
![Page 53: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/53.jpg)
– It is esablished protocols of the Undersea and Hyperbaric Medicine Society.
– Either monoplace or multiplace chamber.– Each session 100% O2 @ 2.4 ATA for 90 min.– Increase the vascularity by 75%
HBO protocol
![Page 54: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/54.jpg)
• Allow healing …. – Angiogenesis.– Inducing fibroplasia and neocellularity.– Promoting survival of osteoprogenitor cells.– Promoting the formation of functional periosteum.
HBO Protocol
![Page 55: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/55.jpg)
Indication of HBO
1. Prophylaxis.. In surgical procedure in irradiated field.
2. Treatment of ORN.3. Before bony and soft tissue reconstruction and
before placement of dental implants in irradiated bone.
4. Treatment of Necrotizing Fascitis, gas gangrene and chronic refractory osteomyelitis.
HBO Protocol
![Page 56: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/56.jpg)
Prophylactic HBO before oral surgical procedure
Marx et al 1991 300 pts Incidence of ORN in non –HBO 30% compared with 5.4% in –
HBO group. HBO is very cost effective
![Page 57: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/57.jpg)
Against:× overall risk of developing ORN with preradiation or postradiation
extractions is quite low.× HBO therapy is expensive.× it is time consuming.
× HBO has not definitely been shown to prevent the development of ORN, and it does not reverse established ORN.
![Page 58: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/58.jpg)
Prophylactic HBO before oral surgical procedure
• 20 sessions before• 100% O2 @2.4ATA-90 min.• Once daily treatment 5 days/week.
• 10 sessions post op.
20/10
![Page 59: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/59.jpg)
Prophylactic HBO before dental implants
Animal and clinical studies treated with HBO showed: • Improved soft tissue wound healing . • Decreased dehiscence after implants with HBO.This study also showed:• Improved torque removal forces of implants.• Greater quantity of bone-implant contact in irradiated rabbit tibias
treated with HBO compared with that not treated.
![Page 60: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/60.jpg)
Against:The potential benefit of HBO therapy balanced against its cost and potential complications doesn’t justify its use.
In 1997, the Journal of Oral and Maxillofacial Surgery highlighted a similar controversy. Keller and Larsen took opposing views. Keller examined 14 studies of implants in radiated tissue without HBO, which had remarkable success.
![Page 61: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/61.jpg)
Evidence supports enhanced long-term survival in all sites, but the clinician must weigh the availability, complications, and added cost in the decision-making process.
![Page 62: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/62.jpg)
Protocol for HBO therapy before implant placement
• Good oral hygiene before &after implantation.
• The use of the longest &widesttype and maximum no. of implants.
• Implant delay until 6 months after radiation.
![Page 63: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/63.jpg)
• Cessation of smoking.• Preop. HBO ( increase integration time by 3
months).• This protocol is the same for maxilla and the
mandible.
Protocol for HBO therapy before implant placement
![Page 64: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/64.jpg)
• Previously integrated implants should be buried before irradiation and subjected to 20 HBO ttt before uncovering.
Protocol for HBO therapy before implant placement
![Page 65: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/65.jpg)
Gidlines of using HBO
![Page 66: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/66.jpg)
Osteoradionecrosis Treatment
Exposed Bone
Stage I30 Session HBO
Stage I ResponderLocal debridment10 Session HBO
1-Bone softens.2-Granulation tissue develops
Bone and mucosa healed
Stage INonresponder
Stage IISurgical debridement
10 Session HBO
Resolution of ORN Resolution of ORN
Exposed Bone with:A- not respond to stageII.B-pt who presents with:1-pathologic Fx or2-orocutaneous Fistula or3-osteolysis to inferior border of the mandible (radiographic).
Stage III30 Session HBO
1-continuity resection.2-Jaw stabilization.3-Soft tissue flap if needed.
10 Session HBO
Resolution of ORN
Continued exposure
Dehiscence, cont. bone exposure
![Page 67: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/67.jpg)
• However, several studies have shown some benefit in using HBO in the management of Stage I and II ORN.
• Most reconstructive surgeons currently use vascularized free tissue transfers instead of HBO therapy in the management of stage III ORN.
![Page 68: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/68.jpg)
Early criticism of microvascular reconstruction of the mandible included:
• inadequate bone stock for prosthetic dental reconstruction,
• prolonged ICU stay and hospitalization, • increased donor site morbidity.
Experience with microvascular reconstruction has lessened these concerns.
![Page 69: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/69.jpg)
Complication of HBO
1-Barotrauma:Middle ear. Nasal sinus.Inner ear .Lung.Teeth.
![Page 70: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/70.jpg)
2-oxygen toxicity:CNS..seizur .Lung.. Pneumothorax &air embolism.
Complication of HBO
![Page 71: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/71.jpg)
3- confinement anxiety.
4- Ocular defect..myopia and catarct growth
Complication of HBO
![Page 72: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/72.jpg)
![Page 73: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/73.jpg)
Contraindication of HBO
![Page 74: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/74.jpg)
Guidelines for tooth extraction in Radio. or chemotherapy pt.
• Perform extraction with minimal trauma.• Within first 4 months of radiotherapy
‘’Golden Window’’.
![Page 75: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/75.jpg)
• Trim bone at wound margins to eliminate sharp edges.
• Obtain primary closure.• Avoid intraalveolar haemostatic packing
agents that can serve as nidus of microbial growth.
Guidelines for tooth extraction in Radio. or chemotherapy pt.
![Page 76: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/76.jpg)
• Transfuse if the platelet count is less than 50,000/mm3.
• Delay if WBC < 2000/mm3. or absolute neutrophil is <1000/mm3. or expected to be this level within 10 days.
• Prophylactic antibiotics (cephalosporin) may be used with extractions are mandatory.
Guidelines for tooth extraction in Radio. or chemotherapy pt.
![Page 77: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/77.jpg)
• Prophylaxis:– Penicillin V 500mg q4h one day pre op.– Continue for at least 3 days post op.
![Page 78: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/78.jpg)
![Page 79: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/79.jpg)
Bisphosphonate
• It is a synthetic analog of inorganic pyrophosphate.• Which has high affinity to calcium.• Accumulate over extended periods in mineralized bone
matrix.
![Page 80: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/80.jpg)
• Used in : – Paget’s disease. – Osteoporosis. – hypercalcemia of malignancy.– Multiple myeloma in bone.– metastatic solid cancer like breast.
![Page 81: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/81.jpg)
• Action :– Arrest bone loss.– Increase bone density. – Decrease bone fracture.
![Page 82: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/82.jpg)
Rout of Administration
•Etidronate (Didronell)•Pamidronate (Aredia)•Zoledronic acid (Zometal)
![Page 83: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/83.jpg)
What does it do?
• Bisphosphonate alter bone remodeling.• The drug is taken up by osteoclasts (cytoplasm).
• Inhibit its function.• Induce apoptotic cell death.
• Inhibits osteoblast mediated osteoclast resorbtion.• Antiangeogenic properties.
![Page 84: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/84.jpg)
![Page 85: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/85.jpg)
• In oral cavity, the maxilla and mandible are subjected to constant stress from masticatory forces.
• The bone becomes brittle and unable to repair physiological micro-fractures occur in human skeleton.
![Page 86: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/86.jpg)
• So BRONJ..as a result from:– Low bone metabolism.– Local trauma– Increase demand for bone repair.– Infection– Hypovascularity.
![Page 87: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/87.jpg)
Table 3. Dental risk factors for osteonecrosis of the jaw (ONJ).° Clinically and radiographically evident periodontitis17,38: severe periodontitis with chronic infection andinflammation of the supporting alveolar bone is a major risk factor for ONJ. This condition may be present in3%–5% of seventh-decade and older adults who still have teeth17° Tooth extraction: up to 60% of cases of ONJ have been reported in patients having had a recent tooth extraction1,2,17,35,38,50,66° Concomitant or past oral infection35,48,66,77,78° Failing root canal treatment with retained periapical infection35° Trauma caused by removable dentures2,35,38,77° Implant placement, past or current1,2,17,78: newly placed implants have a poor healing rate in patients receivingIV bisphosphonates and hence are contraindicated1. Previously placed implants may have a higher rate offailure. This warrants further study
Table 4. Systemic and other risk factors for osteonecrosis of the jaw (ONJ).° Concomitant malignant disease and chemotherapy1,17,38,66,79° Glucocorticoid therapy1,17,35,66,80° Diabetes1,38,81° Advanced age: in review of cases of ONJ in patients with multiple myeloma, there was a 9% increase in therisk of developing ONJ with each decade of life82° Smoking and alcohol need to be evaluated further
![Page 88: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/88.jpg)
Clinical picture of BRONJ
In early stage:• No radiographic manifestation.• Bone exposure • Soft tissue dehiscence.• Secondary infection.• Parasthesia from peripheral nerve compression
Sever pain
![Page 89: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/89.jpg)
BRONJ Staging and Treatment
• At RiskNo apparent exposed/necrotic bone in pt.
treated with oral or I.V bisphosphonate.• Treatment:
– No treatmen.t– Pt. education.
![Page 90: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/90.jpg)
Stage 1:•Exposed /necrotic bone.•Asymptomatic.•No evidence of infection.
Treatment:•Antibacterial mouth rinse.•F/U every 3 months.•Review indication for continued bisphosphonate therapy.•Pt. education.
![Page 91: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/91.jpg)
Stage2:•Exposed/necrotic bone.•Pain and erythema. In the area of exposed bone.•With/without purulent drainage.
•Treatment:•Symptomatic treatment.•Broad spectrum A/B.•Pain control.•Superficial debridement to relieve soft tissue irritation.
![Page 92: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/92.jpg)
Stage3:•Exposed/necrotic bone.•Pain and infection•One or more of the following:•Extraoral fistula.•Osteolysis extending to the mandibular border.
•Treatment: •Broad spectrum A/B.•Pain control.•Superficial debridement/resection for palliation and pain.
![Page 93: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/93.jpg)
Full understanding of the behavior of the cancer as well as the treatment modality available will help you in optimal management of those patient
![Page 94: Management of Cancer patients](https://reader036.vdocument.in/reader036/viewer/2022081413/5471c851b4af9fcd0a8b4cb6/html5/thumbnails/94.jpg)
THANK YOU